CNBC Pro

Eli Lilly obesity drug delivers 20% weight loss, bolstering investment case for new therapies

A woman walks down the street on Michigan Avenue in Chicago, Illinois.
Jeff Haynes | AFP | Getty Images

Clinical trial data released Thursday by Eli Lilly reinforces the belief that a wave of obesity treatments are on the horizon that could be gamechangers for patients struggling to lose weight and perhaps investors as well.

More In Investing trends

CNBC ProInvestment banks trumpet fresh ideas in new second-half stock trades
CNBC ProGoldman picks stocks poised to benefit from the multitrillion-dollar ESG opportunity ahead
CNBC ProConsider hiding out in these tech stocks during a bear market, Bernstein says